DUK-CPG-001

N/A

Report date: 2026/03/26 20:00:17
NME

Base Information

Drug NameDUK-CPG-001
Drug Alias NameDUK-CPG-001
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide
Mechanisms of ActionToll like receptor 9 agonists
TargetsToll like receptor 9
Therapy Area/IndicationsLymphoma, Non-HodgkinHodgkin DiseaseLymphoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesDuke University
China Registration ClassN/A

Develop Information

Active CompaniesAgilent Technologies Inc
Inactive CompaniesDuke University
Active IndicationsLymphomaLeukemia, Myeloid
Inactive IndicationsLymphoma, Non-HodgkinHodgkin Disease

Other Information

ATC CodeN/A
Related LinksN/A